US › Healthcare

Cingulate Inc (CING)

US · Healthcare · Biotechnology

$4.36-0.68%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-5.9M

EPS

$-0.45

EPS estimate

$-0.63

EPS came in at -0.45 against a street estimate of -0.63 — a beat of 28.6%.

Key statistics

Market cap

$70.4M

Forward P/E

0.0

P/B

3.20

Book value

$1.69

EPS (TTM)

$-3.51

52-week high

$11.89

52-week low

$3.16

50-day MA

$5.11

200-day MA

$5.42

Beta

-0.88

Analyst view

Analysts rate Cingulate Inc a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $21.20.

Shareholding

Insiders

28.29%

Institutions

12.59%

Largest institutional holders

Fund	Stake
Vanguard Capital Management, LLC	3.93%
Chicago Partners Investment Group LLC	1.30%
Kestra Advisory Services, LLC	1.04%
Geode Capital Management, LLC	0.99%
Renaissance Technologies Corp	0.88%
Vanguard Fiduciary Trust Co	0.54%
BlackRock Inc	0.37%
BCV Asset Management Inc.	0.35%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Cingulate Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-18.